Sarepta Therapeutics Inc (SRPT)

Cash ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash and cash equivalents	US$ in thousands	428,430	966,777	2,115,870	1,502,650	835,080
Short-term investments	US$ in thousands	1,247,820	1,022,600	0	435,923	289,668
Total current liabilities	US$ in thousands	653,659	619,604	452,733	416,026	264,767
Cash ratio		2.56	3.21	4.67	4.66	4.25

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($428,430K + $1,247,820K) ÷ $653,659K
= 2.56

The cash ratio of Sarepta Therapeutics Inc has shown a decreasing trend over the past five years, declining from 4.25 in 2019 to 2.56 in 2023. This indicates that the company's ability to cover its short-term liabilities with its cash and cash equivalents has weakened over the period. Despite the decrease, the cash ratio remains above 1, suggesting that Sarepta Therapeutics Inc still has sufficient liquid assets to meet its short-term obligations. However, the declining trend warrants further monitoring to assess the company's liquidity position and ability to weather unforeseen financial challenges in the future.